# Jean-Francois Rax > Jean-Francois Rax is a seed investor at Medsenic (Strasbourg) backing Medical and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Medsenic](https://shizune.co/investors/profile/medsenic) - Location: Strasbourg, France - Total investments: 6 - Last investment: Sep 2025 - Lead investor: 83% - Last updated: Aug 2026 Jean-Francois Rax is a seed investor at Medsenic in Strasbourg focused on Medical and Biotechnology. Jean-Francois Rax - Board Member @ Medsenic ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Medical | 4 | 67% | | Biotechnology | 3 | 50% | | Health Care | 2 | 33% | | Pharmaceutical | 2 | 33% | | Biopharma | 1 | 17% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Seed | 3 | 50% | | Grant | 1 | 17% | | Series A | 1 | 17% | | Funding Round | 1 | 17% | ### Country | Country | Investments | Share | | --- | --- | --- | | France | 4 | 67% | | United States | 1 | 17% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | RDS | RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level. | $16.4M | Series A | Sep 29, 2025 | | | SUPERBRANCHE | SUPERBRANCHE is a biotechnology company for the early detection and treatment of metastases through nanotechnological provisions. | $13.5M | | Feb 04, 2025 | | | Rhythm Diagnostic Systems | Many of our team have worked together on different projects and in different companies over the last 30-plus years. We are experienced technology, medical, health care and biotech professionals, with long, successful histories in Silicon Valley and elsewhere. | $1.1M | Seed | Oct 10, 2023 | | | Inoviem Scientific | Inoviem Scientific is a privately-owned contract research biotech (CRB) offering preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Our pioneering technologies allow us to work in any therapeutic field and with any therapeutic compound (small chemical molecules, fragments, proteins,peptides, antibodies, etc). Our clients are any laboratories in the private or academic sphere working to develop therapeutic compounds. Our innovatory force lies with the technologies we have developed, and our strength generally resides in our ability to analyse drug-target interaction to a high degree of precision directly on crude human tissue, thus respecting physiological conditions. Our goal is to be your partner of choice for the development of drug candidates. Our technologies have the potential to bring to light information hidden within crude human tissue obtained from patients or healthy donors. Their use will significantly improve your chances of marketing your drug. As a technollogy and innovation driven CRB, Inoviem Scientific is continuously investing human and financial resources in the development of complementary technologies to bring the best technological, creative and innovative solutions to its clients. This continuous investment will reinforce our analysis power driving Inoviem Scientific to become: From preclinical to clinical: A leading explorer of drug-target interaction! | $713K | Grant | | | | PeptiMimesis | PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors.PeptiMimesis will develop its pipeline against keytargets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest. | $768K | Seed | | | | Inoviem Scientific | Inoviem Scientific is a privately-owned contract research biotech (CRB) offering preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Our pioneering technologies allow us to work in any therapeutic field and with any therapeutic compound (small chemical molecules, fragments, proteins,peptides, antibodies, etc). Our clients are any laboratories in the private or academic sphere working to develop therapeutic compounds. Our innovatory force lies with the technologies we have developed, and our strength generally resides in our ability to analyse drug-target interaction to a high degree of precision directly on crude human tissue, thus respecting physiological conditions. Our goal is to be your partner of choice for the development of drug candidates. Our technologies have the potential to bring to light information hidden within crude human tissue obtained from patients or healthy donors. Their use will significantly improve your chances of marketing your drug. As a technollogy and innovation driven CRB, Inoviem Scientific is continuously investing human and financial resources in the development of complementary technologies to bring the best technological, creative and innovative solutions to its clients. This continuous investment will reinforce our analysis power driving Inoviem Scientific to become: From preclinical to clinical: A leading explorer of drug-target interaction! | $549K | Seed | | | 6 of 6 investments shown. ## Co-investors - [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together - [Critical Path Ventures](https://shizune.co/investors/profile/critical-path-ventures) — VC Fund, 1 deal together - [MACSF](https://shizune.co/investors/profile/macsf) — VC Fund, 1 deal together ## About Medsenic VC Fund · Paris, France Medsenic is a privately held company that manufactures drugs for the treatment of autoimmune diseases. 3 contacts available at Medsenic. | Name | Title | Profile | | --- | --- | --- | | Jean-Francois Rax | Board Member | https://shizune.co/investors/profile/jean-francois-rax | | François Rieger | Co-Founder, Chief Executive Officer & President | https://shizune.co/investors/profile/fran%C3%A7ois-rieger | | Véronique Pomi | Co-Founder, Chief Operating Officer | https://shizune.co/investors/profile/v%C3%A9ronique-pomi | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ## FAQ ### What does Jean-Francois Rax invest in? Jean-Francois Rax invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Grant stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Jean-Francois Rax last invest? The most recent investment recorded for Jean-Francois Rax closed in Sep 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co